SCHEMBL1499622

SCHEMBL1499622

Cc1cc(C(=O)NCCN(C)C)ccc1Nc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.53
IDH1 O75874 1/20 0.51
ALDH1A1 P00352 1/20 0.47
ABL1 P00519 2/20 0.47
FYN P06241 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
BCR P11274 1/20 0.44
MAPK14 Q16539 1/20 0.44
TRPV1 Q8NER1 4/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1499324 0.87 ALDH1A1 (0.51) MCHR1ALDH1A1ABL1FYNSMN1; SMN2
SCHEMBL1499450 0.87 MCHR1 (0.65) MCHR1IDH1ALDH1A1TRPV1
SCHEMBL1499377 0.86 MCHR1 (0.60) MCHR1ABL1KMT2ABCRHTT
SCHEMBL1499251 0.85 MCHR1 (0.46) MCHR1ABL1SMN1; SMN2LMNABCR
SCHEMBL12964418 0.84 MCHR1 (0.47) MCHR1ALDH1A1ABL1BCRTRPV1
SCHEMBL1499543 0.80 MCHR1 (0.48) MCHR1IDH1ALDH1A1ABL1MEN1
SCHEMBL12964300 0.78 PDE4B (0.54) ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL20685241 0.78 IDH1 (0.54) MCHR1IDH1ALDH1A1ABL1FYN
SCHEMBL1499308 0.77 ABL1 (0.53) MCHR1IDH1ABL1FYNBCR
SCHEMBL12964611 0.76 MCHR1 (0.51) MCHR1FYNMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP claimed
US-10130595-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2018-11-20 US claimed
US-20160166519-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CT NATIONALE DE RECH SCIENT (FR) 2016-06-16 US claimed
US-9233931-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2016-01-12 US claimed
CN-101965341-B Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities CT NAT RECHSEARCH SCIENT 2014-07-16 CN claimed
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) 2014-06-05 US claimed
JP-2011509280-A 2011-03-24 JP claimed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US claimed
CN-101965341-A Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities CT NAT RECHSEARCH SCIENT 2011-02-02 CN claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO claimed
EP-3536691-B1 CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2022-10-05 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
CN-101965341-A Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities CT NAT RECHSEARCH SCIENT 2011-02-02 CN disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10130595-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, SF3B1 MCHR1 3957/4885IDH1 1981/4885ALDH1A1 1901/4885
US-20160166519-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, RBM22, SF3B1 MCHR1 3957/4885IDH1 1981/4885ALDH1A1 1901/4885
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A MCHR1 3616/4885IDH1 2367/4885ALDH1A1 2047/4885
US-20140155436-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 MCHR1 2907/4885IDH1 3380/4885ALDH1A1 3049/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 MCHR1 2907/4885IDH1 3380/4885ALDH1A1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.